Neurolixis

Neurolixis Inc. is a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders.

Neurolixis, Inc. is a clinical stage specialty pharmaceutical company focused on developing medicines targeting unmet disorders of the nervous system. The Company has two therapeutic candidates in clinical development: The most advanced compound, NLX-112, is a potential symptomatic treatment for dyskinesia in Parkinson’s disease (PD) ready for Phase 2 clinical studies. The Company also has NLX-101 in Phase I clinical development for Rett Syndrome, a neurodevelopmental disorder that affects roughly 16,000 children in the US and 50,000 in the industrial world.